Cargando…
Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial
Gait and balance disturbances typically emerge in advanced Parkinson’s disease with generally limited response to dopaminergic medication and subthalamic nucleus deep brain stimulation. Therefore, advanced programming with interleaved pulses was put forward to introduce concomittant nigral stimulati...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692032/ https://www.ncbi.nlm.nih.gov/pubmed/23757762 http://dx.doi.org/10.1093/brain/awt122 |
_version_ | 1782274554892124160 |
---|---|
author | Weiss, Daniel Walach, Margarete Meisner, Christoph Fritz, Melanie Scholten, Marlieke Breit, Sorin Plewnia, Christian Bender, Benjamin Gharabaghi, Alireza Wächter, Tobias Krüger, Rejko |
author_facet | Weiss, Daniel Walach, Margarete Meisner, Christoph Fritz, Melanie Scholten, Marlieke Breit, Sorin Plewnia, Christian Bender, Benjamin Gharabaghi, Alireza Wächter, Tobias Krüger, Rejko |
author_sort | Weiss, Daniel |
collection | PubMed |
description | Gait and balance disturbances typically emerge in advanced Parkinson’s disease with generally limited response to dopaminergic medication and subthalamic nucleus deep brain stimulation. Therefore, advanced programming with interleaved pulses was put forward to introduce concomittant nigral stimulation on caudal contacts of a subthalamic lead. Here, we hypothesized that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata improves axial symptoms compared with standard subthalamic nucleus stimulation. Twelve patients were enrolled in this 2 × 2 cross-over double-blind randomized controlled clinical trial and both the safety and efficacy of combined subthalamic nucleus and substantia nigra pars reticulata stimulation were evaluated compared with standard subthalamic nucleus stimulation. The primary outcome measure was the change of a broad-scaled cumulative axial Unified Parkinson’s Disease Rating Scale score (Scale II items 13–15, Scale III items 27–31) at ‘3-week follow-up’. Secondary outcome measures specifically addressed freezing of gait, balance, quality of life, non-motor symptoms and neuropsychiatric symptoms. For the primary outcome measure no statistically significant improvement was observed for combined subthalamic nucleus and substantia nigra pars reticulata stimulation at the ‘3-week follow-up’. The secondary endpoints, however, revealed that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata might specifically improve freezing of gait, whereas balance impairment remained unchanged. The combined stimulation of subthalamic nucleus and substantia nigra pars reticulata was safe, and of note, no clinically relevant neuropsychiatric adverse effect was observed. Patients treated with subthalamic nucleus and substantia nigra pars reticulata stimulation revealed no ‘global’ effect on axial motor domains. However, this study opens the perspective that concomittant stimulation of the substantia nigra pars reticulata possibly improves otherwise resistant freezing of gait and, therefore, highly warrants a subsequent phase III randomized controlled trial. |
format | Online Article Text |
id | pubmed-3692032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-36920322013-06-25 Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial Weiss, Daniel Walach, Margarete Meisner, Christoph Fritz, Melanie Scholten, Marlieke Breit, Sorin Plewnia, Christian Bender, Benjamin Gharabaghi, Alireza Wächter, Tobias Krüger, Rejko Brain Original Articles Gait and balance disturbances typically emerge in advanced Parkinson’s disease with generally limited response to dopaminergic medication and subthalamic nucleus deep brain stimulation. Therefore, advanced programming with interleaved pulses was put forward to introduce concomittant nigral stimulation on caudal contacts of a subthalamic lead. Here, we hypothesized that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata improves axial symptoms compared with standard subthalamic nucleus stimulation. Twelve patients were enrolled in this 2 × 2 cross-over double-blind randomized controlled clinical trial and both the safety and efficacy of combined subthalamic nucleus and substantia nigra pars reticulata stimulation were evaluated compared with standard subthalamic nucleus stimulation. The primary outcome measure was the change of a broad-scaled cumulative axial Unified Parkinson’s Disease Rating Scale score (Scale II items 13–15, Scale III items 27–31) at ‘3-week follow-up’. Secondary outcome measures specifically addressed freezing of gait, balance, quality of life, non-motor symptoms and neuropsychiatric symptoms. For the primary outcome measure no statistically significant improvement was observed for combined subthalamic nucleus and substantia nigra pars reticulata stimulation at the ‘3-week follow-up’. The secondary endpoints, however, revealed that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata might specifically improve freezing of gait, whereas balance impairment remained unchanged. The combined stimulation of subthalamic nucleus and substantia nigra pars reticulata was safe, and of note, no clinically relevant neuropsychiatric adverse effect was observed. Patients treated with subthalamic nucleus and substantia nigra pars reticulata stimulation revealed no ‘global’ effect on axial motor domains. However, this study opens the perspective that concomittant stimulation of the substantia nigra pars reticulata possibly improves otherwise resistant freezing of gait and, therefore, highly warrants a subsequent phase III randomized controlled trial. Oxford University Press 2013-07 2013-06-11 /pmc/articles/PMC3692032/ /pubmed/23757762 http://dx.doi.org/10.1093/brain/awt122 Text en © The Author (2013). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Weiss, Daniel Walach, Margarete Meisner, Christoph Fritz, Melanie Scholten, Marlieke Breit, Sorin Plewnia, Christian Bender, Benjamin Gharabaghi, Alireza Wächter, Tobias Krüger, Rejko Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial |
title | Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial |
title_full | Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial |
title_fullStr | Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial |
title_full_unstemmed | Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial |
title_short | Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial |
title_sort | nigral stimulation for resistant axial motor impairment in parkinson’s disease? a randomized controlled trial |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692032/ https://www.ncbi.nlm.nih.gov/pubmed/23757762 http://dx.doi.org/10.1093/brain/awt122 |
work_keys_str_mv | AT weissdaniel nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT walachmargarete nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT meisnerchristoph nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT fritzmelanie nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT scholtenmarlieke nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT breitsorin nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT plewniachristian nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT benderbenjamin nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT gharabaghialireza nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT wachtertobias nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial AT krugerrejko nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial |